These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Management for TNF failure].
    Author: Mukai M.
    Journal: Nihon Rinsho; 2007 Jul; 65(7):1299-307. PubMed ID: 17642247.
    Abstract:
    At the dawn of biologics era, we just have strong weapons against rheumatoid arthritis (RA). After the introduction of anti-tumor necrosis factor (TNF) agents (infliximab, etanercept, and adalimumab), we have experienced the revolutional effects on the treatment for RA. In spite of these excellent effects, there are a proportion of patients refractory to these agents. While we can choose another anti-TNF agent for them at present, many biologics for other targets such as CTLA4 (abatacept), IL-6 (tocilizumab), and CD20 (rituximab) are on the waiting list in the very near future. These agents have been reported to have the strong efficacy to TNF failure patients with RA. After developing many agents for the pathophysiologic targets of RA, we will expect to select one of them for each patient dependent on their predictive value of RA in the future.
    [Abstract] [Full Text] [Related] [New Search]